We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLK
101
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$5.4M 0.08%
239,624
-11,561
-5% -$252K
ZLAB icon
102
Zai Lab
ZLAB
$2.28B
$5.3M 0.08%
159,400
+69,400
+77% +$2.66M
VRNA
103
DELISTED
Verona Pharma
VRNA
$5.27M 0.08%
+262,683
New +$5.67M
AZN icon
104
AstraZeneca
AZN
$262B
$4.97M 0.07%
35,800
+1,550
+5% +$209K
BMRN icon
105
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.71M 0.07%
48,445
-12,240
-20% -$1.27M
SGEN
106
DELISTED
Seagen Inc. Common Stock
SGEN
$4.6M 0.07%
22,700
+74
+0.3% +$11.9K
SUPN icon
107
Supernus Pharmaceuticals
SUPN
$2.79B
$4.45M 0.06%
122,881
+11,835
+11% +$455K
MTEM
108
DELISTED
Molecular Templates, Inc.
MTEM
$4.27M 0.06%
748,667
-3,200
-0.4% -$21.6K
LLY icon
109
Eli Lilly
LLY
$1.05T
$3.7M 0.05%
10,764
-291
-3% -$98.1K
JNJ icon
110
Johnson & Johnson
JNJ
$609B
$3.55M 0.05%
22,905
-3,122
-12% -$504K
AMWL icon
111
American Well
AMWL
$221M
$3.45M 0.05%
73,109
-24,512
-25% -$1.57M
ABBV icon
112
AbbVie
ABBV
$450B
$2.74M 0.04%
17,176
+976
+6% +$149K
COR icon
113
Cencora
COR
$59.9B
$2.55M 0.04%
15,910
+5,700
+56% +$904K
SGHT icon
114
Sight Sciences
SGHT
$274M
$2.5M 0.04%
286,284
-8,322
-3% -$92.4K
KOS icon
115
Kosmos Energy
KOS
$1.33B
$2.37M 0.03%
318,300
– –
GH icon
116
Guardant Health
GH
$20.7B
$1.93M 0.03%
82,197
-53,258
-39% -$1.52M
CYTK icon
117
Cytokinetics
CYTK
$10.9B
$1.91M 0.03%
54,200
– –
ALKS icon
118
Alkermes
ALKS
$8.79B
$1.81M 0.03%
64,200
+28,700
+81% +$782K
CVS icon
119
CVS Health
CVS
$137B
$1.7M 0.02%
22,814
-181,391
-89% -$15.2M
LH icon
120
Labcorp
LH
$23.2B
$1.6M 0.02%
8,134
+4,258
+110% +$876K
KRYS icon
121
Krystal Biotech
KRYS
$10.5B
$1.47M 0.02%
18,300
– –
BBIO icon
122
BridgeBio Pharma
BBIO
$15.9B
$1.37M 0.02%
+82,600
New +$963K
KRTX
123
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.33M 0.02%
7,300
– –
ISEE
124
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.29M 0.02%
52,900
+11,100
+27% +$243K
VRDN icon
125
Viridian Therapeutics
VRDN
$1.99B
$1.17M 0.02%
46,100
– –
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.